SLC10A3 drives glioblastoma progression by remodeling the immunosuppressive microenvironment and promoting M2 macrophage migration
Frontiers in Oncology · 13.05.2026 · 16
DOI: 10.3389/fonc.2026.1742452 ↗Kurz gefasst
Fachartikel in der Zeitschrift Frontiers in Oncology, online erschienen am 13.05.2026. Verfasst von Shuhui Chen und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Otorhinolaryngology-Head and Neck Surgery, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi, China. Die Arbeit nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Introduction
Glioblastoma (GBM) is an aggressive brain tumor with poor prognosis, limited therapeutic options, and a highly immunosuppressive microenvironment. This study investigated the clinical significance and biological role of SLC10A3 in GBM progression and immune evasion.
Methods
Bulk transcriptomic data from TCGA and CGGA cohorts were analyzed to assess SLC10A3 expression and prognostic value. Functional enrichment, single-cell RNA sequencing, and cell–cell communication analyses were performed to explore SLC10A3-related pathways and cellular distribution. In vitro and in vivo experiments were conducted to evaluate the effects of SLC10A3 knockdown on GBM malignant phenotypes and macrophage recruitment.
Results
SLC10A3 was significantly overexpressed in GBM and associated with poor prognosis. Enrichment analyses linked SLC10A3 to PI3K-Akt, NF-κB, HIF-1 signaling, macrophage infiltration, and T-cell suppression. Single-cell analysis showed SLC10A3 enrichment in tumor-associated astrocytes and macrophages, with enhanced astrocyte–macrophage crosstalk through MIF, MDK, and extracellular matrix remodeling pathways. SLC10A3 knockdown inhibited GBM cell proliferation, migration, and invasion, induced cell cycle arrest and apoptosis, reduced M2 macrophage migration, and suppressed xenograft tumor growth.
Discussion
SLC10A3 may promote GBM aggressiveness and immune evasion by regulating malignant phenotypes and macrophage-associated immunosuppression, suggesting its potential as a therapeutic target for GBM.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Otorhinolaryngology-Head and Neck Surgery, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi, China.
- Department of Comprehensive Radiation Oncology, Jiangxi Key Laboratory of oncology, Jiangxi Cancer Hospital, The Second Affiliated Hospital of Nanchang Medical College, Jiangxi Cancer Institute, Nanchang, Jiangxi, China.
- Department of science and education, The First People's Hospital of Jiangxia District, Hubei University of Medicine, Shiyan, Hubei, China.
- Department of Thoracic Surgery, The Second Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nanchang, China.
Zitieren
APA
Chen, S., Qin, D., Lin, H., Ding, T., Liu, W., Yan, Z., Wang, L., & Kou, B. (2026). SLC10A3 drives glioblastoma progression by remodeling the immunosuppressive microenvironment and promoting M2 macrophage migration. Frontiers in Oncology, 16. https://doi.org/10.3389/fonc.2026.1742452
Vancouver
Chen S, Qin D, Lin H, Ding T, Liu W, Yan Z, et al. SLC10A3 drives glioblastoma progression by remodeling the immunosuppressive microenvironment and promoting M2 macrophage migration. Frontiers in Oncology. 2026;16. doi:10.3389/fonc.2026.1742452
BibTeX
@article{Chen2026,
author = {Chen, Shuhui and Qin, Daogang and Lin, Hanyang and Ding, Taohui and Liu, Wei and Yan, Ziqi and Wang, Lingting and Kou, Bo},
title = {SLC10A3 drives glioblastoma progression by remodeling the immunosuppressive microenvironment and promoting M2 macrophage migration},
journal = {Frontiers in Oncology},
year = {2026},
volume = {16},
doi = {10.3389/fonc.2026.1742452}
}
EUVIMED